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Tremendous  progress  has  been  made  over  the  last  ten years  on  East  Coast  fever  (ECF)  research.  Publi-
cation  of  a reference  genome  sequence  of  Theileria  parva,  the  causative  agent  of ECF,  has  led  to  a more
thorough  characterization  of  the  genotypic  and  antigenic  diversity  of the  pathogen.  It also  facilitated
identiﬁcation  of  antigens  that are  targets  of  bovine  major  histocompatibility  complex  class  I restricted
cytotoxic  T-lymphocytes  (CTLs),  induced  by  a live  parasite-based  infection  and  treatment  method  (ITM)
vaccine.  This  has  led  to  improved  knowledge  of  epitope-speciﬁc  T-cell responses  to  ITM that  most  likely
contribute  to  the phenomenon  of  strain-speciﬁc  immunity.  The Muguga  cocktail  ITM  vaccine,  which  pro-
vides  broad-spectrum  immunity  to ECF  is now  a registered  product  in three  countries  in eastern  Africa.
Effort  is directed  at improving  and  scaling  up  the production  process  to make  this  vaccine  more  widelynfection and treatment
ntigens
available  on  a  commercial  basis  in the region.  Meanwhile,  research  to develop  a subunit vaccine  based  on
parasite neutralizing  antibodies  and  CTLs  has been  revived  through  convening  of a research  consortium
to  develop  proof-of-concept  for a next  generation  vaccine.  Many  new  scientiﬁc  and  technical  advances
are  facilitating  this  objective.  Hence,  the  next  decade  promises  even  more  progress  toward  an  improved
control  of  ECF.
©  2016  The  Authors.  Published  by  Elsevier  GmbH.  This  is an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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. Introduction
Theileriosis caused by the hemoprotozoan pathogen Theileria
arva still ranks ﬁrst among the tick-borne diseases of cattle in
ub-Saharan Africa (Minjauw and McLeod, 2003). Organisms in
he genus Theileria are found in many wild and domesticated
nimals (reviewed in Norval et al., 1992). They are phylogeneti-
ally most closely related to members of the Babesia genus and
all in the order Piroplasmida under the phylum Apicomplexa
Gou et al., 2012; Kuo et al., 2008; Lack et al., 2012; Levine,
985; Morrison, 2009a; Schnittger et al., 2012). Theileria parva, T.
nnulata and T. lestoquardi feature prominently among pathogenic
pecies of Theileria that affect domesticated ruminants (reviewed
n Norval et al., 1992). They share a unique biology of being
ble to transform a subset of infected mononuclear host cells,
hich can be cultured in vitro as persistently infected cell lines.
ot all species of Theileria can transform mononuclear host cells,
.g., T. orientalis, T. mutans and T. velifera. If such species cause
isease it is mainly due to multiplication of the parasite life-
ycle stage within red blood cells (reviewed in Norval et al.,
992).
It is believed that T. parva co-evolved with the African Cape
uffalo, in which infection does not cause disease, and has under-
one a “host jump” to cattle, where it causes the disease referred
o as East Coast fever (ECF) (reviewed in Norval et al., 1992). Differ-
nces in the epidemiology, clinical symptoms, and parasitological
arameters in cattle associated with different T. parva infections
ave led, in the past, to sub-speciation of T. parva. This nomencla-
ure was abandoned (Perry and Young, 1993), and parasite isolates
re now described as cattle- or buffalo-derived (Anon, 1988a,b).
owever, in southern Africa, cattle-derived T. parva is associated
ith a less virulent disease than ECF, called January disease in
imbabwe (reviewed in Latif and Hove, 2011). The disease caused
y buffalo-derived T. parva is called Corridor disease, and it is
sually more acute than ECF (reviewed in Norval et al., 1992).
nother characteristic of the latter is that it is extremely difﬁ-
ult to maintain buffalo-derived parasites through serial passage
etween ticks and cattle, whereas this is relatively easy with cattle-
erived parasite isolates (Young and Purnell, 1973). This scenario
s complicated by the presence of multiple strains in cattle- and
uffalo-derived parasite populations, with possible co-infections
etween them in individual animals (Conrad et al., 1987; Mans
t al., 2015; Oura et al., 2003, 2004, 2005, 2011). In evolutionary
erms, the change in host-species is likely to have occurred rel-
tively recently as cattle were introduced to Africa ∼5000 years
go (Epstein, 1971). Although molecular data do not currently sup-
ort sub-species status of T. parva (Allsopp et al., 1993; Conrad
t al., 1989), the biological observations suggest the presence of
wo segregating populations of the parasite (see also Mans et al.,
015). The importance of the parasite buffalo reservoir in eval-
ating approaches to ECF control is variable depending on the
arming system, geographical region and wildlife-cattle interface
Gachohi et al., 2012; Norval et al., 1992). The remainder of this
eview concentrates on aspects of the biology of T. parva and
ecent advances in vaccine-related research, which is helping to
hape the development of a subunit vaccine for the control of
CF. .  .  .  .  . . . .  . .  .  . . . . . .  .  . . . . . .  . . . . .  . . .  . . . .  . . .  . . . . .  . . . .  .  . . . .  . .  . . .  .  .  .  . . .  .  .  . . . . . .  . . .  560
2. A background to East Coast fever, a lethal bovine disease
present in sub-Saharan Africa
In the early 1900s, Dr. Arnold Theiler recognized that Theileria
parva was the causative agent of ECF in South Africa (Theiler, 1912).
He distinguished ECF from Redwater caused by Babesia, and identi-
ﬁed the principal tick vector that transmits T. parva as Rhipicephalus
appendiculatus. The disease was  associated with cattle imported
from East Africa, and caused high levels of morbidity and mortality
(reviewed in Norval et al., 1992). South Africa eradicated the dis-
ease through a strict control of cattle movement, surveillance with
slaughter of infected cattle, and fencing to restrict buffalo to game
parks. Occasional outbreaks of buffalo-derived T. parva disease still
occur, but appear to be self-limiting in nature (Mbizeni et al., 2013;
Thompson et al., 2008). It has not been possible to implement such
measures in other countries as a sustainable method of disease
control. Hence, ECF remains an acute and usually lethal disease
present in 12 countries in eastern, central and southern Africa,
including Burundi, Democratic Republic of Congo, Kenya, Malawi,
Mozambique, Rwanda, South Sudan, Tanzania, Uganda, Zambia and
Zimbabwe (reviewed in Norval et al., 1992; Malak et al., 2012), and,
more recently, in the Comoro Islands (De Deken et al., 2007).
On a regional basis ECF kills ∼1 million cattle/year with annual
economic losses of ∼USD300 million (McLeod and Kristjanson,
1999). These estimates were derived many years ago and current
impacts are likely to be much larger. ECF can establish in new areas
due to a wider distribution of the tick vector and/or suitable tick
habitats (Norval et al., 1992), as occurred in the Comoro Islands
in 2004 (De Deken et al., 2007). Recent political changes in South
Sudan has led to a growing incidence of ECF in a naïve popula-
tion of cattle with mortality rates close to 80% (Malak et al., 2012;
Marcellino et al., 2012). This spread poses a direct threat to cat-
tle in the Central African Republic and regions to the west. To the
east, although ECF has not been described in Ethiopia, this coun-
try houses the largest population of cattle in Africa, and predictive
models indicate that the tick vector could thrive in the Ethiopian
highlands (Norval et al., 1991).
There is some evidence that Bos taurus cattle are more sus-
ceptible to ECF than Bos indicus animals, and there may  be breed
differences in susceptibility to disease (Norval et al., 1992). The
severity of ECF caused by T. parva is parasite dose-dependent and
there also appear to be differences in the threshold of infectivity
in individual cattle (Cunningham et al., 1974; Dolan et al., 1984).
These observations could obscure true host genetic differences in
susceptibility to ECF. Cattle that exhibit mild or moderate ECF clin-
ical symptoms are considered resistant to disease, while those that
exhibit severe clinical reactions are judged to be susceptible (Anon,
1988a). Cattle can spontaneously recover from infection, usually
after a mild or moderate reaction, and are solidly immune to re-
infection. This phenomenon contributes to endemic stability of
the disease in indigenous cattle in regions where there is contin-
ual transmission of the parasite (Medley et al., 1993; Norval et al.,
1992). Animals that recover from ECF do not usually eliminate the
infection, they remain as carriers of the parasite and a source of
infections to ticks (Kariuki et al., 1995). The recent observation of
an apparent protective effect in young cattle due to co-infections
with non-pathogenic Theileria raises interesting new questions on
-borne
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he epidemiology of ECF (Thumbi et al., 2014; Woolhouse et al.,
015).
. Theileria parva exhibits a complex life cycle
Understanding the life cycle of the parasite is important as it
rovides information that may  be used to improve disease con-
rol strategies, and for identifying novel targets of intervention.
heileria parva undergoes a series of sequential developmental
hanges in the tick and bovine host (Fig. 1). These changes have
een primarily characterized at the morphological level through
legant electron microscopy studies (Fawcett et al., 1981, 1982a,
987; Shaw and Tilney, 1992; Shaw, 1996b). Unfortunately, not
uch is known about the molecular details of parasite-host cell
nteraction or pathways that control parasite differentiation into
ifferent life-cycle stages. Rhipicephalus appendiculatus is a three-
ost tick and the principal vector for transmission of T. parva,
hich occurs trans-stadially (reviewed in Norval et al., 1992).
hus, tick larvae and nymphs acquire an infection from the piro-
lasm stage present in red blood cells (RBCs) in infected cattle.
nfected nymphs and adults transmit sporozoites, the life-cycle
tage infective to cattle, during feeding. In vitro, sporozoites can
ind and rapidly enter lymphocytes via a passive “zippering pro-
ess” of sporozoite and host cell membranes (Fawcett et al., 1982c;
awcett and Stagg, 1986; Shaw, 1996a, 1997). Unlike other api-
omplexan organisms, T. parva sporozoites are non-motile and
pherical/ovoid in shape with a diameter of 0.75–1.5 m (Fawcett
t al., 1982a,b). They do not have well developed apical com-
lexes and host cell entry is not orientation speciﬁc (reviewed in
haw, 2003). Discharge from sporozoite secretory organelles, rhop-
ries/microspheres, is seen after host-cell entry, and coincides with
apid escape from the surrounding host membrane. Sporozoites
ifferentiate into the schizont stage, which is a multinucleated
tage that resides free in the host cell cytoplasm surrounded by
 basket of host cell microtubules that seem to be nucleated
y parasite molecules (reviewed in Shaw, 2003). These infected
ells acquire a metastatic, cancer-like phenotype and are the pri-
ary cause of pathology (reviewed in Dobbelaere and Heussler,
999). Sporozoites also enter macrophages and dendritic cells,
ut only develop to an early stage of the schizont (Shaw et al.,
993).
Schizonts undergo a process of merogony to produce mero-
oites, which are released by host cell rupture. Merozoites invade
BCs, where they develop into the piroplasm stage. The mecha-
ism of merozoite entry into RBCs is similar to that of sporozoite
ntry into lymphocytes and merozoites develop into the piro-
lasm stage, free in the RBC cytoplasm (Shaw and Tilney, 1995).
iroplasms undergo a limited number of cell divisions (Conrad
t al., 1986) and anemia due to destruction of infected RBCs is
ot a prominent feature of ECF (reviewed in Norval et al., 1992).
he piroplasm stage is infective to ticks and differentiation to
ametes seems to occur post-ingestion in the tick gut (reviewed in
orval et al., 1992). Following fusion of macro- and micro-gametes,
ygotes enter cells of the tick gut epithelium and develop into
otile kinetes, which are released into the tick hemocel. Sporo-
ony occurs in the e-cells in type III acini (Fawcett et al., 1982b).
elease of Theileria sporozoites from the salivary glands occurs
s a trickle between day 4–8 post-attachment (Shaw and Young,
995). Approximately 30,000–50,000 sporozoites develop in an
nfected acinus (Fawcett et al., 1982a,b). All life cycle stages of
. parva,  except the zygote, are haploid in nature and zygotes
ndergo a two-step meiotic division (Gauer et al., 1995). The
exual cycle of T. parva in the tick vector results in genera-
ion of extensive parasite genotypic and antigenic diversity (see
elow). Diseases 7 (2016) 549–564 551
4. Host cell transformation and morbidity caused by the
schizont life-cycle stage
ECF is described as an acute, lymphoproliferative disease associ-
ated with pathology induced by schizont-infected cells, and death
is usually caused by pulmonary edema (reviewed in Norval et al.,
1992). Full schizogony of T. parva only occurs in B- and T-cells
(Baldwin et al., 1988), where the parasite causes the host cell to
proliferate. The schizont divides in synchrony with the host cell so
that daughter host cells remain infected (Irvin et al., 1982). In vivo
and in vitro most transformed cell lines are of the T-cell lineage,
and higher levels of pathogenicity are associated with infected T-
cells rather than infected B-cells (Morrison et al., 1996). Growth
of infected cells is rapid, independent of exogenous growth fac-
tors, and completely dependent on the presence of live parasites
as treatment with anti-theilerial drugs, e.g., buparvaquone, results
in cells reverting to a non-proliferative state (Brown et al., 1989a;
Dobbelaere et al., 1991; Heussler et al., 1992).
In contrast to T. parva, T. annulata transforms
macrophages/dendritic cells and B-cells, but not T-cells
(Dobbelaere and Heussler, 1999; Spooner et al., 1989). These
observations indicate that a two-way communication between
parasite and host cell type plays a role in the process of host
cell transformation. However, the situation appears to be more
complex as not all infected lymphocytes become transformed
(Morzaria et al., 1995; Rocchi et al., 2006). It is beyond the
scope of this review to cover excellent research on the topic of
molecular mechanisms that contribute to host cell transformation
and the reader is directed to several publications (Chaussepied
and Langsley, 1996; Chaussepied et al., 2010; Cheeseman and
Weitzman, 2015; Dobbelaere and Rottenberg, 2003; Heussler
et al., 2002; Marsolier et al., 2015; Medjkane et al., 2014; Shiels
et al., 2006; Tretina et al., 2015; von Schubert et al., 2010).
Understanding the mechanisms by which Theileria organisms
cause mammalian cells to transform has an obvious relevance to
cancer biology. Disruption of these mechanisms may  offer novel
drug-targets for the control of ECF (Marsolier et al., 2015).
5. Genotypic diversity is a hallmark of Theileria parva
A reference genome sequence for T. parva and T. annulata was
published in 2005 (Gardner et al., 2005; Pain et al., 2005). A
reference sequence for other Theileria species (Hayashida et al.,
2012; Kappmeyer et al., 2012) and whole genome sequence data
from other strains/isolates of T. parva have also been published
(Hayashida et al., 2013; Henson et al., 2012; Norling et al., 2015).
These resources provide essential baseline data to study T. parva
population structure, antigenic diversity, and facilitate reverse vac-
cinology approaches for vaccine development. In contrast to other
Apicomplexa, e.g., Plasmodium and Babesia (Jackson et al., 2014;
Singh et al., 2014), a prominent role for members of the major T.
parva multi-gene families (Gardner et al., 2005) as antigens remains
to be established.
In general, buffalo-derived parasites are more diverse than
cattle-derived parasites. A number of loci (Allsopp and Allsopp,
1988; Bishop et al., 1995, 1998; Conrad et al., 1987; Katzer et al.,
2010; Pelle et al., 2011) and variable number of tandem repeat
(VNTR) markers (mini- and micro-satellites) derived from the T.
parva genome sequence data have been used as markers to deter-
mine parasite diversity (Oura et al., 2003, 2004, 2005, 2011; Patel
et al., 2011). Such studies are inﬂuenced by the distribution, den-
sity, and type of markers across the genome, and current results
are preliminary in nature. A study of parasite population struc-
ture using VNTRs (Oura et al., 2003, 2004, 2005, 2011) indicated
that there was  no obvious relationship between geographical origin
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Fig. 1. Life-cycle of Theileria parva. The ﬁgure illustrates the different life cycle stages of the parasite as it cycles through the mammalian and tick host. The ﬁgure was
inspired by ﬂuorescence and electron micrograph images of the parasite life cycle (Fawcett et al., 1982a; Norval et al., 1992; von Schubert et al., 2010). Stages of the life
cycles  are not drawn to scale. Sporozoites enter lymphocytes where they develop to the schizont stage, a process that results in host cell transformation resulting in clonal
expansion of schizont-infected cells. The schizont stage is polyploid and multiple schizont nuclei are observed during host cell interphase. It is during the metaphase period
of  the cell cycle that schizont division occurs (Irvin et al., 1982). Some of the schizonts undergo merogony, giving rise to merozoites, which mature into the piroplasm stage in
RBCs,  and are infective to ticks. Tick larvae and nymphs acquire an infection by feeding on infected cattle or buffalo, and transmit the parasite as the next tick instar, nymphs and
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nd level of genetic similarity between parasite isolates, such that
ifferent parasite isolates from the same farm exhibited distinct
enotypes. Older cattle tended to have a larger number of differ-
nt parasite genotypes than younger ones, which tended to have
 pre-dominating genotype (Oura et al., 2005). Some geographi-
al sites exhibited a sub-structure in parasite populations, others
id not, and some exhibited an epidemic structure characteristic
f recent predominating infections (Oura et al., 2005). Thus, it has
een suggested that cattle movement, their interface with buffalo,
nd parasite transmission rates are likely to play a major role in
etermining T. parva parasite population structures (Oura et al.,
003).
VNTR mapping the progeny from two cattle-derived parasite
loned stocks after transit through the tick vector has led to a
enetic linkage map  for T. parva (Katzer et al., 2011), and identi-
cation of regions with higher (hot spots) and lower (cold spots)
ates of recombination than a genome-wide average. Using a phys-
cal size of ∼8.3 Mbp  of the T. parva genome (Gardner et al., 2005)
he total genetic size was calculated at 1683.8 cM (Katzer et al.,
011). This map  provides an important reference for placement of
enes into regions with different rates of recombination. Whole
enome sequence data from a few different cattle- and buffalo-
erived parasite isolates mapped to the reference genome has
ed to identiﬁcation in excess of 500,000 single-nucleotide poly-
orphisms (SNPs) (Hayashida et al., 2013; Henson et al., 2012).
NP density/kbp was 2–4-fold higher in buffalo-derived parasites,
ore prevalent in coding than non-coding regions, and has led
o identiﬁcation of SNP-rich and SNP-poor chromosomal regions
Hayashida et al., 2013). Sequence data have also identiﬁed recom-
ination events, and a large number of crossover events lead to
ene conversion (Henson et al., 2012). Interestingly, phylogenetic
elationships as measured by SNPs detected in the coding regions
f 200 random selected genes place the sequences derived from
uffalo-derived parasites into a separate cluster from the sequences
f cattle-derived parasites (Norling et al., 2015). These data begin
o reveal the genetic complexity of the parasite nuclear genome,
vents leading to diversity between different strains, and a list of
rotein coding genes that are under different rates of evolutionary
ressure (Hayashida et al., 2013; Henson et al., 2012). Unraveling
ow such observations relate to genes that play a role in medi-
ting host and vector interactions, the differences in the biology
etween cattle- and buffalo-derived parasites, and to immunity to
CF, remains a fascinating prospect.
. A live sporozoite-based vaccine for the control of ECF via
nfection and treatment
There is solid evidence from both ﬁeld observations as well as
rom laboratory-based studies that cattle acquire robust immu-
ity to ECF following recovery from infection (reviewed in Norval
t al., 1992). As the infection and treatment method (ITM) name
mplies, the process involves deliberate infection of cattle with con-
omitant drug treatment. The latter controls but does not kill the
arasite permitting generation of a protective acquired immune
esponse. The ITM process has evolved over several decades start-
ng in South Africa. Initial studies were based on injecting cattle
ith heavily parasitized spleen and lymph node homogenates
btained from infected cattle slaughtered in the last stages of the
isease (Theiler, 1912). This gave way to the ﬁnding that prolonged
dults. There is no transovarial transmission of the parasite (reviewed in Norval et al., 19
here  sporogony occurs. Mature merozoites (Mz) and sporozoites (Sz) originate from a m
espectively. See main text for additional details. The vertebrate host cell nucleus is col
nd  micronemes in merozoites are depicted as small dark green dots inside the parasite
rawings and artistic creation by N. Svitek. Diseases 7 (2016) 549–564 553
intra-venous tetracycline cover during natural T. parva infections
resulted in immunity to ECF (Neitz, 1953). The process of using
triturated infected tick suspensions, a method for cryopreserving
them, and titration of the infectivity of frozen sporozoite stabilates
(Cunningham et al., 1973, 1974) provided a source of standardized
parasite material for vaccination. Development and optimization
of ﬁrst short, and subsequently long-acting formulations of oxy-
tetracyclines to control the infections played an important role in
development of the ITM protocol (Radley, 1981). It has been demon-
strated that at low dilutions the Boleni isolate of T. parva from
Zimbabwe can be used to immunize cattle in the absence of tetra-
cycline (reviewed in Latif and Hove, 2011), but it has been difﬁcult
to replicate this in other parasite isolates.
It was discovered early on that exposure of immune cattle to
parasite isolates from different geographical sites could result in
break-through infection and disease in some animals, giving rise to
the concept of strain/isolate speciﬁc immunity (Young et al., 1973).
Although individual parasite isolates can be placed in different
cross-immunity groups, there is usually 20–30% cross-protection
between them (Morzaria, 1996). Combining different isolates
broadens the vaccine coverage of ITM. Hence, the Muguga cocktail,
which consists of three T. parva isolates (called Muguga, Serengeti-
transformed and Kiambu-5) was shown to provide broad-spectrum
immunity to ECF (Radley et al., 1975a,b). Developed in principle
almost 50 years ago, the Muguga cocktail ITM vaccine has had
a checkered history in its translation to a commercially available
product as it is time consuming and difﬁcult to produce, requires
a liquid nitrogen cold chain for its storage, is potentially a lethal
product if not given with adequate antibiotic cover, and is expen-
sive.
The hurdles in producing and delivery of the Muguga cock-
tail can be overcome, and the vaccine has proved to be highly
effective in controlling ECF (Di Giulio et al., 2009). In response to
a FAO/multi-donor regional program, the International Livestock
Research Institute (ILRI) produced ∼600,000 doses of the cocktail
in two batches, called FAO1 and FAO2 (Morzaria et al., 1997). Use of
a higher oxytetracycline dose than before reduced the number of
clinical reactors to the vaccine, eliminating need for a second dose
of antibiotic treatment and visit by the service provider after immu-
nization. This, together with more extensive use of the vaccine in
pastoral areas of Tanzania has played a major role in increasing
the demand for the cocktail vaccine (Di Giulio et al., 2009). The
next commercial batch of the cocktail of ∼1 million doses, called
ILRI08, was  made by ILRI (Patel et al., 2015) in recognition of deplet-
ing stocks of the FAO vaccine batches, and in response to a major
initiative to invest in commercialization of the Muguga cocktail
(GALVmed, 2010). An indication of the success of this revitaliza-
tion is that the ILRI08 batch was sold out in just ﬁve years, and
re-investments in the Center for Ticks and Tick-Borne Diseases
(CTTBD) in Malawi to become the site of production and distri-
bution of future batches of the cocktail as a commercial enterprise
are near to fruition (GALVmed, 2014). The Muguga cocktail has been
registered as a vaccine in Malawi, Kenya and Tanzania, and no doubt
more lessons will be learnt as vaccine production is scaled up and
delivered through public and private veterinary services.It is puzzling how three T. parva isolates in the Muguga cocktail,
selected from a limited geographical area, have shown protec-
tion across such a wide geographical area (Di Giulio et al., 2009;
Norval et al., 1992; Radley et al., 1975a,b). Using a very limited
92). Kinetes, the ﬁnal products of the sexual cycle, invade the tick salivary glands
ultinucleated residual body (Rb) during the process of merogony and sporogony,
ored in purple and the parasite nucleus is in orange. Microspheres in sporozoites
. Host cell microtubules in the dividing schizont-infected cell are drawn in green.
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anel of ﬁve VNTR markers on schizont-infected cell lines estab-
ished from the components of the Muguga cocktail revealed the
resence of 17 genotypes in the cocktail (Patel et al., 2011). The
accine strains present in the ILRI08 cocktail batch also exhibit
imited diversity of genes encoding the known candidate vaccine
ntigens (Hemmink, Weir, MacHugh, Graham, Shiels, Toye, Mor-
ison and Pelle, unpublished manuscript). Recent whole genome
equence data derived from the piroplasm stage of parasite compo-
ents of the Muguga cocktail revealed only 957 SNPs between the
erengeti-transformed and Muguga sequence, but close to 40,000
NPs between the Kiambu-5 and Muguga sequence (Norling et al.,
015). The sequence differences between Serengeti-transformed
nd Muguga were primarily restricted to sub-telomeric regions,
hile those between Kiambi-5 and Muguga were located across the
enome. The latter altered the sequences of almost half of the par-
site protein coding genes. A curious feature of the sequence data
as an absence of mixed sequences, suggesting that the Serengeti-
ransformed and Kiambu-5 piroplasm DNA sequenced were clonal
n nature (Norling et al., 2015). Although the true level of hetero-
eneity in the Muguga cocktail remains to be determined, the very
igh degree of sequence similarity between Serengeti-transformed
nd Muguga questions the origin of the former, and the value of its
rotective role in the Muguga cocktail (Norling et al., 2015). Unfor-
unately, our current tools for typing parasite genotypic diversity
o not predict cross-immunity proﬁles. Nevertheless, molecular
arkers can be used to determine identity, and as quality con-
rol tools to ensure that the composition of strains present in the
uguga cocktail remain relatively constant during the complex
roduction process of the vaccine.
As mentioned previously, parasite isolates placed in different
ross-immunity groups usually exhibit 20–30% cross-protection
etween them (Morzaria, 1996). Sequential immunization by ITM
ith single isolates in different cross-immunity groups provides
dditive immunity (Taracha et al., 1995b). This suggests that some
rotective antigens are shared between different parasite isolates,
nd the breadth of the immune response can be expanded in
esponse to new infections. Novel genotypes can be found in cat-
le vaccinated with the Muguga cocktail (Oura et al., 2004). This
ay  help to further broaden the spectrum of immunity to strains
f the parasite not present in the cocktail. Currently, there is no
imple answer as to whether buffalo-derived parasites will break-
hrough the Muguga cocktail. For example, the cocktail has proved
ighly effective in pastoral areas of Tanzania where cattle are likely
o be exposed to buffalo-derived parasites (Di Giulio et al., 2009).
ecent experiments in Kenya demonstrate that this immunity is
usceptible to buffalo-derived parasites on the Ol Pejeta ranch in
aikipia district (Sitt et al., 2015) but not in the Narok County area
Mukholi, Kitala, Gathuma, Kidula, Turasha, Mbwira, Mugambi,
iara, in preparation). Hence, buffalo-derived parasites may  remain
 confounding factor in some areas where the Muguga cocktail is
eployed and will have to be evaluated on an empirical basis.
There still remains lingering concern about the long-term
mpact that exotic T. parva strains might have on local parasite
opulations when used outside the region of origin of vaccine
trains leading to a debate on the use of autogenous ITM vac-
ines versus cocktail vaccines (Geysen, 2008; McKeever, 2007). For
xample, following some apparent complications due to use of the
uguga cocktail, Zambia has chosen to use local isolates from the
astern and southern provinces to control ECF (Nambota et al.,
994). Fortunately, in Zimbabwe, a single parasite stock (Boleni)
rovides broad-spectrum immunity within the country (reviewed
n Latif and Hove, 2011). The concern of using exotic parasites
evolves around the observation that cattle can remain as carriers
f vaccine stocks, and that these may  recombine with local parasite
trains during tick transmission giving rise to new more viru-
ent parasite variants and upset the balance of endemic stability. Diseases 7 (2016) 549–564
However, the Muguga cocktail ITM vaccine has been used in differ-
ent livestock production systems and geographical areas over many
years (Uilenberg, 1999), without any major reports of a change
in the epidemiology of ECF or large-scale failure of the vaccine,
although it has been shown that components of the cocktail can
establish itself locally (Oura et al., 2007). What is required is to
either dispel or conﬁrm the concerns by establishing monitoring
experiments where a good baseline study of the clinical nature
of the disease and a comprehensive study of the existing para-
site genotypes are studied prior to vaccination, and longitudinal
monitoring is carried out for several years. In this way  the risk
from the use of live parasites in exotic locations could be better
assessed. For the moment ITM remains the only vaccine based solu-
tion available for the control of ECF. Efforts are underway to develop
next generation subunit vaccines but these are several years
away.
7. Chemotherapy of East Coast fever
Thirty years later buparvaquone still remains the front line com-
mercial drug of choice for the treatment of T. parva (McHardy et al.,
1985) and T. annulata infections (Dhar et al., 1986). However, to
be completely effective the drug needs to be administered early
in infection (Martins et al., 2010). As with other hydroxynaptho-
quinones the drug most likely functions by inhibiting electron
transport through the mitochondrion (Birth et al., 2014). Resis-
tance to buparvaquone has been described in T. annulata (Mhadhbi
et al., 2010) and correlates with mutations in the cytb gene
(Mhadhbi et al., 2015; Shariﬁyazdi et al., 2012). Hence, the recent
identiﬁcation of a T. annulata nuclear gene encoding a secreted
peptidyl-prolyl isomerase, as an additional target of buparvaquone
resistance was  unexpected (Marsolier et al., 2015). These ﬁndings
are of concern for the future control of T. annulata as drug resis-
tance could spread. Although buparvaquone resistance in T. parva
remains to be documented it may  just be a question of time before
this occurs. Effort should be made to identify new anti-theilerial
drugs, leveraging on the drive to develop new anti-malarial drugs
(Burrows et al., 2014).
8. A role for humoral immune responses in mediating
immunity to East Coast fever
Cattle exposed to T. parva infection develop an antibody
response to several parasite proteins. Among these speciﬁcities,
antibodies to the polymorphic immunodominant molecule (PIM)
have proved to be the most reliable in measuring exposure to T.
parva. PIM can be polymorphic in size between different T. parva
strains (Shapiro et al., 1987; Toye et al., 1995a), but there is suf-
ﬁcient conservation of sequences between the variants for PIM to
function as a diagnostic antigen (Katende et al., 1998; Toye et al.,
1996). Hence, an ELISA assay based on recombinant PIM from the
Muguga stock of the parasite is routinely used to determine preva-
lence (Gitau et al., 2000), and sero-conversion to the ITM vaccine
(Patel et al., 2015).
Early studies on passive transfer of sera from immune cat-
tle failed to protect against challenge (Muhammed et al., 1975).
In addition, immunization with parasite antigen failed to protect
against ECF (Wagner et al., 1974), leading to a consensus in the
ECF literature that antibodies did not play a major role in mediat-
ing immunity to the disease. However, indirect evidence for a role
for antibodies in mediating immunity to ECF was  derived from the
observation that cattle can develop sporozoite neutralizing anti-
bodies (Musoke et al., 1982). However, this activity is seen after
multiple sporozoite exposure, suggesting weak immunogenicity of
the relevant target/s.
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Table 1
Experimental vaccine trials in cattle using different p67 constructs and antigen delivery systems.
Immunogen p67 antigen
sequence
Dose Route Adjuvant Animal numbers Control Challenge dose and
stabilate number
Outcome (SR
reduction)
References
NS1-p67 (E. coli) 1–709 5 × 1 mg s.c. 3% SA (Merck) 9 immunized
10 controls
Non immunized
and
NS1 in saponin
LD68, Muguga 3087 66% Musoke et al. (1992)
BEV-p67 (insect) 1–709 5 × 300 g CFA/IFA or
3% SA (Merck)
6  immunized
3 controls
Non immunized LD68, Muguga 3087 66% Nene et al. (1995)
NS1-p67 (E. coli) 1–709 5 × 600 g 3% SA (Merck) 12 immunized10  controls Non immunized
LD68, Muguga 3087 58% Nene
et al.
(1996)11 immunized
10  controls
1:8 dilution
Marikebuni 3014
55%
p67  in attenuated Salmonella Mix of:
1–709
20–709
20–622
3–4 × 1–2 × 109
c.f.u
i.m. None 10 immunized
15 controls
Non immunized
and  Salmonella
immunized
Equivalent to one
infected acinus,
Muguga 3087 or 4133
25% Heussler et al.
(1998)
p67 in attenuated
Salmonella
21–699 3 × 109–1011 c.f.u.
secreting p67
i.m.
None
3 immunized
3 controls Non immunized LD80 Muguga 4133
66% Gentschev et al.
(1998)
21–699 3 × 109–1011 c.f.u.
secreting p67
oral 3 immunized
3 controls
33%
Mix of:
1–709
20–709
20–622
3  × 109–1011 c.f.u.
p67
i.m. 3 immunized
3 controls
33%
V-67-GPI in recombinant
vaccinia virus
1–643 2 × 5 × 108 p.f.u
i.d. None
7 immunized
7 controls
Non immunized
LD70, Muguga 4133
0% Honda et al. (1998)
V583-IL2 in recombinant
vaccinia virus
1–583 2 × 5 × 108 p.f.u 10 immunized
20 controls
Non immunized
and  V-IL2
20%
V-67-GPI + V-IL2 in
recombinant vaccinia virus
1–643 2 × 5 × 108 p.f.u 7 immunized
7 controls
Non-immunized 51%
p67C  (E. coli) 572–651 3 × 450 g
s.c.
RWL (Pﬁzer Animal
Health)
7 immunized
7 controls RWL immunized LD70, Muguga 4133
70% Bishop et al. (2003)
P67N (E. coli) 21–225 3 × 450 g 7 immunized
7 controls
13%
P67635 (E. coli) 17–635 3 × 450 g 7 immunized
7 controls
40%
GFP:p67DSS 21–651 2 × 100 g
s.c.
SA or WOE (both
Intervet
International)
26 immunized (13
SA  and 13 WOE)
15 controls
GFP in SA or WOE
LD70, Muguga 4133
51% in SA and
43% in WOE
Kaba et al. (2005)
GP64:p67C (cell extract) 572–651 2 × 10 g SA (Intervet
International)
13 immunized
15 controls
GFP in SA 36%
p67635 (E. coli) 17–635 3 × 450 g
s.c.
RWL (Pﬁzer
Animal Health)
and ISA206
(SEPPIC)
42 immunized
35 controls
Ovalbumin in RWL
or ISA206 LD70, Muguga 4133
40% Musoke et al. (2005)
p67C (E. coli) 572–651 3 × 450 g 14 immunized
35 controls
69%
p67635 and p67C (E. coli)
ﬁeld experiment
17–635 and
572–651
respectively
3 × 450 g RWL (Pﬁzer
Animal Health)
83 immunized
50  controls
Ovalbumin in RWL 26%
Results from published p67 vaccine trials in Bos indicus cattle are presented. The outcome of challenge is expressed as a percentage of cattle that were immune to challenge and was based on the severity of clinical reactions to
challenge, e.g., severe reactors are classiﬁed as susceptible to ECF. This was calculated by subtracting the percentage of non-severe reactors in the control group from that in the immunized group. Abbreviations: c.f.u. (colony
forming  units); CFA (complete Freund’s adjuvant); GFP (green ﬂuorescent protein); i.d. (intradermal); IFA (incomplete Freund’s adjuvant); i.m. (intramuscular); LD (lethal dose); p.f.u. (plaque forming units); SA (saponin); s.c.
(subcutaneous); SR (severe reactor); WOE  (water-in-oil emulsion).
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.1. Identiﬁcation and characterization of antigens that are
argets of neutralizing antibodies
Characterization of a series of murine mAbs that neutralized
porozoite infectivity in in vitro assays identiﬁed a ∼67 kDa protein,
alled p67, as a major surface antigen of sporozoites, and as the pri-
ary target of neutralizing mAbs (nmAbs) (Dobbelaere et al., 1984,
985; Musoke et al., 1984). The p67 protein probably contributes
o the process of host cell recognition and entry, during which it is
hed (Webster et al., 1985). It is encoded by a single copy gene, and is
redicted to contain an N-terminal signal peptide and a membrane
nchor domain (Nene et al., 1992). No sequence variation was found
n this gene in a set of cattle-derived T. parva isolates (Nene et al.,
996). Allelic polymorphisms in p67 sequences are observed in
uffalo-derived T. parva and in samples directly collected from cat-
le (Sibeko et al., 2010). However, it is not entirely clear if the latter
arasite types can be maintained through serial passage between
icks and cattle. Sequence identity between full-length p67 alleles is
reater than 90% (Nene et al., 1996). This suggests that the recently
escribed diversity in a few p67 B-cell epitopes (Obara et al., 2015)
s unlikely to negatively inﬂuence the ability of p67 to function
s a cross-protective immunogen, a prediction that remains to be
alidated.
Host MHC  class I molecules appear to facilitate sporozoite entry
s mAbs to them can neutralize sporozoite infectivity, but they are
nlikely to function as unique host cell receptors as sporozoites
o not bind or enter all nucleated cells (Shaw et al., 1995). More
ecently the function of p67 as a primary ligand has been brought
nto question. This is based on the observation that T. parva Chi-
ongo sporozoites only binds to CD8+ T-cells yet the gene coding
or p67 is identical in sequence to that of T. parva Muguga sporo-
oites, which bind B-cells and all subsets of T-cells (Tindih et al.,
010, 2012). Comparative molecular studies between sporozoites
f these two T. parva isolates should help to resolve their differences
n host cell tropism.
The PIM antigen was identiﬁed as a second target of nmAbs
hrough serendipity. A series of mAbs raised to the schizont stage
as found to be speciﬁc for PIM, and has been used to type differ-
nt parasite strains (Minami et al., 1983; Shapiro et al., 1987). The T.
arva PIM gene sequence is highly polymorphic in both cattle- and
uffalo-derived parasites (Baylis et al., 1993; Geysen et al., 2004;
oye et al., 1995a). Some of the mAbs were subsequently found
o neutralize sporozoite infectivity (Toye et al., 1995a), and lin-
ar epitopes they bound were mapped by Pepscan analysis (Toye
t al., 1996). PIM is localized to sporozoite rhoptries/micronemes
Toye et al., 1996). In contrast, PIM is located on the schizont sur-
ace (Baylis et al., 1993; Shapiro et al., 1987), most likely as a
olecule that spans the surface membrane several times. The cDNA
equence of sporozoite and schizont PIM is identical, so it is not
lear how the molecule is targeted to different cellular compart-
ents in the different life cycle stages. It is possible that nmAbs
ain access to PIM in a transient manner during sporozoite inva-
ion to inhibit its function. However, the immunobiology of the
IM antigen is quite complex as rats immunized with recombinant
IM make neutralizing antibodies (Toye et al., 1995b) but cattle
o not, although the bovine antibodies to PIM also bind to peptide
equences bound by nmAbs (Toye et al., 1996). A role for PIM as
n anti-sporozoite vaccine antigen remains to be explored, as it is
ossible that immunization of cattle with different constructs of
IM may  induce neutralizing antibodies.
A third candidate target of neutralizing antibodies, a 32 kDa pro-
ein, was identiﬁed through immunoprecipitation of biotin labeled
porozoites with the mAb  4C9. This protein proved to be a homolog
f the Tams1 antigen of T. annulata, a major surface antigen of
erozoites (Shiels et al., 1995). Bovine antisera to recombinant
32 did not induce neutralizing antibodies and immunized cattle Diseases 7 (2016) 549–564
were susceptible to challenge (Skilton et al., 2000). Hence, work on
this antigen was  discontinued. The role of two other immunogenic
sporozoite antigens (p104 and p150) as candidate vaccine antigens
has not been evaluated (Iams et al., 1990; Skilton et al., 1998).
Based on the large number of apicomplexan parasite molecules
that generally play a role in host cell entry (Counihan et al., 2013),
it is possible that additional T. parva candidate sporozoite vaccine
targets remain to be discovered.
8.2. Immunization with recombinant p67 can protect against
East Coast fever
Full-length and smaller regions of the p67 protein from the
Muguga parasite isolate have been expressed in a recombinant
form using a variety of different expression systems (Table 1).
The high degree of sequence conservation of this protein makes
it an intrinsically more attractive candidate vaccine antigen than,
e.g., the PIM antigen. Unfortunately, the full-length p67 antigen
has proved to be an extremely difﬁcult molecule to express in its
native format as a recombinant protein in E. coli (Bishop et al.,
2003; Musoke et al., 1992), Pichia pastoris (unpublished data), insect
cells (Kaba et al., 2002, 2005; Nene et al., 1995) or mammalian
cells (Honda et al., 1998, and unpublished data). Under labora-
tory conditions, recombinant p67 protein with adjuvants given via
the sub-cutaneous route has been found to consistently induce
immunity to ECF. Table 1 also provides a summary of results from
experimental vaccine trials carried out over several years, includ-
ing those derived from a small number of studies with bacterial or
viral antigen delivery systems.
Experimental laboratory trials have mainly used a needle chal-
lenge of sporozoites from the Muguga isolate. The dose was  titrated
to provide a lethal dose 70% (LD70) challenge, which in control
animals represented a 100% infectivity with ∼70% of the cattle
undergoing a severe ECF reaction (Musoke et al., 1992). Relative to
control groups, cattle immunized with recombinant antigen have
given consistent results exhibiting a range of immunity to ECF from
13 to 70% (Table 1). Immunization with p67 protects against a chal-
lenge with sporozoites from the Marikebuni isolate (see below),
which in ITM studies falls in a different cross-immunity group to
the Muguga isolate (Irvin et al., 1983). Immunization with recom-
binant p67 protein even protects against a cross-species challenge
with T. annulata sporozoites (Hall et al., 2000). Surprisingly, p67C,
an 80 amino acid section toward the C-terminal end of the protein,
induces equivalent levels of immunity to full-length p67 (Bishop
et al., 2003). Cattle exhibit a range of ECF clinical symptoms from
non-reactors to severe symptoms, with only the latter classiﬁed as
susceptible to disease (Anon, 1988a). All cattle generate high levels
of antibody titers to p67, but in most experiments there has been
no consistent correlate of various antibody assays with immunity
(Musoke et al., 1992; Nene et al., 1996, 1999).
Field trials exposing p67 immunized cattle to natural
tick/parasite challenge have been carried out at three sites in Kenya.
In these experiments, about 50% of the immunized cattle and 25%
of the control animals exhibited immunity to ECF (Musoke et al.,
2005). While there was  a statistically signiﬁcant level of immunity
that could be ascribed to the vaccine, the overall level of immunity
in the ﬁeld relative to the laboratory challenge data was  low, as
under the ﬁeld conditions some control cattle naturally recovered
from infection. These results are qualitatively different to those
reported from a ﬁeld trial in Zambia, where immunized and con-
trol cattle were equally susceptible to ECF (Schetters et al., 2014).
However, immunized cattle were immune to ECF when given a
sporozoite needle challenge. It is difﬁcult to reconcile the differ-
ences in ﬁeld results between the experiments in Kenya and Zambia
as different antigen doses, adjuvants, and cattle types were used.
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We  ﬁrmly believe that p67 remains a strong candidate vac-
ine antigen, but research is required to increase the efﬁcacy of
he current p67 antigen formulation/immunization scheme. Under
aboratory conditions, it is presumed that sterilizing immunity
as induced in a small number of cattle immunized with p67,
s they exhibited no reaction on challenge (Musoke et al., 1992).
his is not a desirable outcome of a vaccine as this is likely to
isrupt endemic stability of the disease. The lack of an in vitro cor-
elate with immunity hampers efforts to improve the efﬁcacy of
67, as immunogenicity studies alone do not predict the outcome
f challenge data. Efforts are underway to determine if different
ypes of correlates of immunity (Plotkin, 2010) can be devel-
ped.
. A role for cellular immune responses in mediating
mmunity to East Coast fever
Development of the ITM vaccine gave rise to a robust and repro-
ucible research model. Summarizing studies initiated in the late
970s, there is now very good evidence that classical CD8+ MHC
lass I restricted cytotoxic T-lymphocytes (CTLs) that kill schizont-
nfected cells play a major role in mediating immunity primed by
TM (Morrison and Goddeeris, 1990; Morrison, 2009b). The in vivo
mportance of cellular responses in mediating immunity to ECF was
stablished in passive transfer experiments of thoracic duct leuco-
ytes from immune animals to their naïve twins, which conferred
esistance to challenge (Emery, 1981). These studies were reﬁned
y demonstrating that immunity was associated with transfer of
D8+ enriched cells from efferent lymph following mAb-mediated
omplement lysis of CD4+ cells,  T-cells and B-cells (McKeever
t al., 1994).
As mentioned previously, the ITM vaccine induces strain speciﬁc
mmunity. Most of what we know about the nature of this response
erives from studies using the T. parva Muguga and Marikebuni par-
site isolates, which fall in different cross-immunity groups (Irvin
t al., 1983). In brief, these studies demonstrated that there was a
arked correlation between the in vitro CTL strain speciﬁcity to kill
he different parasite isolates and cross-protection (Taracha et al.,
995a). There was immuno-dominance in the antigen speciﬁcity
f the CTL response that was inﬂuenced by the parasite antigenic
ype (Taracha et al., 1995a,b). In addition, the majority of the CTL
esponse was often restricted by one BoLA class-I allele, with a ten-
ency of some alleles to dominate the immune response over others
reviewed in Morrison et al., 2015).
The contribution of other cellular immune responses or innate
esponses to immunity induced by ITM has not been extensively
haracterized (reviewed in Morrison et al., 2015). CD4+ T-cells
Baldwin et al., 1987; Brown et al., 1989b,c, 1990) and  T-cells
Daubenberger et al., 1999) show marked responses post-ITM vac-
ination, but their roles in directly mediating immunity to ECF
emain to be fully characterized. The former are likely to play a
ole in priming the CTL response (Taracha et al., 1997) and the lat-
er can lyse schizont-infected cells (Daubenberger et al., 1999). The
heer numbers of  T-cells in cattle leads to speculation that these
ells could contribute to immunity via cross reactivity toward dif-
erent T. parva strains, as MHC  does not restrict the lytic response
f these cells (Daubenberger et al., 1999). This is consistent with
hat is known about  T-cells in other mammals (Adams et al.,
015). Efforts are underway by others to identify CD4+ T-cell anti-
ens, but little is known about the  antigens, which in other
ystems have been identiﬁed as lipids or phosphoantigens (Adams
t al., 2015). Interestingly, T. annulata schizonts express a large
umber of surface molecules that are phosphorylated (Wiens et al.,
014). The role of other innate cellular immune responses to infec-
ion (reviewed in Morrison et al., 2015), including a novel subset Diseases 7 (2016) 549–564 557
of NKp46+CD3+ cells (Connelley et al., 2014), remains to be fully
characterized.
9.1. Identiﬁcation and characterization of CD8+ T-cell antigens
The antigen speciﬁcity of CD8+ T-cells is mediated by their T-
cell receptor (TCR), which bind to peptide-MHC class I complexes
at the surface of target cells (reviewed by Rossjohn et al., 2015).
These peptides, usually from 8 to 9 amino acid residues in length,
are derived from proteosomal degradation of antigens and bind to a
peptide-binding groove in the MHC  molecule (reviewed by Neefjes
et al., 2011). Methods for the identiﬁcation of T. parva CTL anti-
gens in a high-throughput manner were established fairly recently
(Graham et al., 2007a). Brieﬂy, this involved transfection of sch-
izont cDNA made from candidate gene sequences mined from the
reference T. parva Muguga genome sequence, or the transfection
of random pools of clones from a Muguga schizont cDNA library
into antigen presenting cells. Transfected cells were co-cultured
with CTL lines generated from cattle immunized by ITM with the
Muguga parasite isolate. De-convoluting the components of pooled
cDNA that were positive in an IFN- ELISpot assay led to the identi-
ﬁcation of individual parasite cDNA encoding a CTL antigen. The
BoLA class-I heavy chain allele restricting the CTLs was deﬁned
by co-transfection of parasite cDNA with different BoLA class-I
cDNA. Finally, overlapping synthetic peptides were used to map
the location of CTL epitopes. This ﬁrst round of screening deﬁned 8
antigens, labeled Tp1 to Tp8, and mapped 11 CTL epitopes restricted
by one of seven different BoLA class I alleles (Table 2) (Akoolo
et al., 2008; Graham et al., 2006, 2007a, 2008). Since then three
more CTL antigens have been characterized, Tp9, Tp10 and Tp12
(cited in Morrison et al., 2015). Some of the Tp antigens have a
predicted function, including housekeeping functions. Not all of
the Tp antigens encode a predicted signal peptide raising ques-
tions on how these antigens gain access to the host cell MHC class I
antigen processing pathway. Interestingly, in T. annulata a member
of the subtelomeric variable secreted protein (SVSP) gene family,
labeled Ta11, has been identiﬁed as a CTL antigen (MacHugh et al.,
2011). This provides the ﬁrst evidence that members of a multi-
gene family in T. parva may  play a role in the immune response to
infection.
The immunoscreens for CTL antigens were carried out using less
than a dozen BoLA haplotypes, as deﬁned by serology (Oliver et al.,
1989) Classical BoLA class I genes are located on bovine chromo-
some 23 (Brinkmeyer-Langford et al., 2009) and expressed from
six different loci (Codner et al., 2012). There is no co-dominant
expression of the six alleles and usually no more than three will be
expressed in a given haplotype (Codner et al., 2012). Some of the
CTL lines used in the screens did not yield positive data (Graham
et al., 2006, 2007a). The Immuno-Polymorphism-Database (IPD-
MHC) houses ∼100 BoLA class I sequences (Robinson et al., 2010),
and there is little doubt that the repertoire of bovine BoLA class I
alleles is much higher in number. This indicates that many more
T. parva antigens/epitopes, from both cattle- and buffalo-derived
parasites, remain to be characterized. The few antigens identi-
ﬁed so far have helped to unravel some of the complexity of the
immunobiology of T. parva CTL antigens (see below). The recent
availability of recombinant BoLA class I molecules (Hansen et al.,
2014) has allowed the “on demand” production of peptide-MHC
class-I tetramers and ELISA-based peptide-MHC binding assays
(Svitek et al., 2014). These permit in vitro and ex vivo epitope speciﬁc
T-cell studies using ﬂow cytometry, where co-staining with various
markers of interest can be used to describe the phenotype of epi-
tope speciﬁc CD8+ T-cells (Svitek et al., 2014; Wendoh et al., 2014).
Such data will provide important information on CTLs induced by
ITM and experimental vaccines.
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Table 2
A list of known T. parva CTL antigens and restricting BoLA class-I alleles.
Antigen Antigen annotation a Antigen length Signal peptide b Restricting BoLA
class-I allele
CTL epitope References
Tp1 Hypothetical 543 NO 6*01301 and
6*01302
214VGYPKVKEEML224 Graham et al. (2008)
Tp2 Hypothetical 174 YES
6*04101 29EELKKLGML37 Svitek et al. (2014)
Unknown 40DGFDRDALF48 Nene et al. (2012)
2*01201 49KSSHGMGKVGK59 Graham et al. (2008)
BoLA-T2c c 96FAQSLVCVL104 Graham et al. (2008)
2*01201 98QSLVCVLMK106 Graham et al. (2008)
Unknown 138KTSIPNPCKW147 Akoolo et al. (2008)
Tp4 -TCP1 579 NO 3*00101 328TGASIQTTL336 Graham et al. (2008)
Tp5 eIF-1A 155 NO BoLA-T5 d 87SKADVIAKY95 Graham et al. (2008)
Tp7 Hsp90 721 NO BoLA-T7 c 206EFISFPISL214 Graham et al. (2008)
Tp8 Cysteine proteinase 440 NO 3*00101 379CGAELNHFL387 Graham et al. (2008)
Tp9 Hypothetical 334 YES 1*02301 67AKFPGMKKSK76 e Nene et al. (2012)
The antigens and CTL epitopes were identiﬁed from the Muguga strain of T. parva as brieﬂy reviewed in the text. Data presented include antigen name, antigen annotation,
the  length of each antigen in amino acid residues and presence of a predicted signal sequence for secretion. If known, the BoLA class-I allele (Robinson et al., 2010) that
presents the CTL epitope and the sequence of the CTL epitope is also listed.
a -TCP1 (eta subunit of T complex protein 1), eIF-1A (translation elongation initiation factor 1A), Hsp90 (heat shock protein 90), hypothetical is of unknown function.
b Predicted using the SignalP 4.1 server (http://www.cbs.dtu.dk/services/SignalP/).
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d Unassigned BoLA class-I allele, but the 1-2  domain sequence of the BoLA-T5
e Initially reported as a 10-mer, more recent data indicate the epitope is the 9-m
.2. A role for NetMHCpan in the identiﬁcation and
haracterization of CTL epitopes
The NetMHCpan algorithm (Hoof et al., 2009) can play a useful
ole in the prediction of bovine CTL epitopes (Nene et al., 2012). We
ecently reported on optimization of NetMHCpan using data gen-
rated by measuring the binding of all possible nonameric peptides
o nine recombinant BoLA class I molecules (Hansen et al., 2014).
he data generated a motif for peptides that bind each BoLA class I
olecules and identiﬁed anchor residues, which play a more criti-
al role in peptide binding. Based on such parameters NetMHCpan
ssigns a score to peptide sequences that can bind to a given MHC
olecule (Hoof et al., 2009). NetMHCpan predicted that Tp229–37
ather than Tp227–37 (Graham et al., 2006) is likely to be the epitope
hat binds to BoLA-6*04101 (Hansen et al., 2014). It also predicted
hat the Tp587–95 epitope bound by BoLA-T5 could also be bound
y BoLA-1*02301, an allele originally identiﬁed as presenting an
pitope on Tp9 (Table 2). We  experimentally veriﬁed these predic-
ions (Hansen et al., 2014; Svitek et al., 2014). In the context of CTL
esponses to T. annulata, the BoLA-1*02301 allele has been shown
o present epitopes on Ta9 and Ta5, which are homologs of the Tp9
nd Tp5 antigens of T. parva (MacHugh et al., 2011).
.3. Epitope speciﬁcity of the CTL response in cattle immunized by
he infection and treatment method
With the identiﬁcation of CTL antigens it has been possible to re-
ssess the phenomenon of immuno-dominance in cattle immune
o ECF. Almost 70% of the CTL response to the Muguga parasite iso-
ate in cattle homozygous for BoLA-A18 haplotype is directed to a
ingle epitope on the Tp1 antigen, while the response in BoLA-A10
omozygous cattle is directed to one epitope on the Tp2 antigen,
ith no detectable response to Tp2 in the BoLA-A18 cattle type
r to Tp1 in the BoLA-A10 animals (MacHugh et al., 2009). T-cell
eceptor analysis has revealed that the CTL response is polyclonal
n nature with predominant clonotypes responding to either the
p1214–224 or Tp249–59 epitope (Connelley et al., 2011; Macdonald
t al., 2010). The Tp2 antigen contains a second epitope, Tp298–106,
estricted by BoLA-2*01201 (Table 2), yet the CTL were directed is identical to the 1-2  domain sequence of 1*00902.
FPGMKKS (Svitek et al., in preparation).
mainly to the N-terminal epitope. The speciﬁcities of the remaining
CTL in these cattle are yet to be deﬁned, and the relative role of the
dominant versus less-dominant speciﬁcities in mediating immunity
to ECF remains to be determined. These studies highlight extreme
skewing of CTL responses in these cattle, which presumably con-
tributes to the phenomenon of strain speciﬁc immunity induced by
ITM. Unfortunately, there has not been extensive characterization
of the inﬂuence of BoLA-type on the speciﬁcity of CTL responses in
cattle that are heterozygous at the BoLA locus, or on the speciﬁcity
of CTL responses to infection with mixed parasite isolates, e.g.,  the
Muguga cocktail.
Alanine scanning experiments of the peptide Tp1214–224 and
Tp249–59 epitopes with different CTL clones highlight the impor-
tance of different anchor residues in the peptide binding to BoLA,
and the inﬂuence of peptide-BoLA recognition by different TCRs
(Connelley et al., 2011; Macdonald et al., 2010). It has also been
demonstrated that animals possessing BoLA-6*01302, which dif-
fers from BoLA-6*1301 by a single amino acid substitution in the
peptide binding groove still presents the Tp1214–224 epitope (Svitek
et al., 2015). Sequencing of Tp genes from different cattle- and
buffalo-derived parasites has revealed extensive antigenic diver-
sity in the Tp antigens (Morrison et al., 2015; Pelle et al., 2011). The
ability of variant sequences to function as cross-reactive epitopes
will depend on the molecular ﬂexibility of the peptide-MHC-TCR
interaction. For example, in the context of the respective BoLA class
I allele, variants of the Tp249–59 epitope seem to be less tolerated
than variants of Tp1214–224 (Connelley et al., 2011; Macdonald et al.,
2010; Steinaa et al., 2012). In some cases amino acid substitutions
may  inﬂuence the proteolytic processing of antigens to generate
the relevant epitopes (Morrison et al., 2015). These data indicate
that effort is needed to produce a denser map  of T. parva CTL anti-
gens that contribute to strain speciﬁc and cross-reactive responses.
This should aid the selection of antigens required to prime broad-
spectrum immunity to ECF.9.4. The challenge of priming CD8+ CTLs in cattle
Attempts to induce CTL in cattle that kill autologous schizont-
infected cells using the Tp antigens have, in general, not been
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Table  3
Experimental vaccine trials in cattle using schizont antigens.
Delivery system Immunogen Dose Route Animal
numbers
Control Challenge Outcome References
CP/MVA and
DNA/MVA
Tp1, Tp2, Tp4,
Tp5 and Tp8
0.5 mg DNA or
108 p.f.u. CP
prime, boost
5 × 108 p.f.u.
MVA
DNA i.d./CP and
MVA  s.c.
12 DNA/MVA
immunized
12 CP/MVA
immunized
4 controls
Immunized
with vaccine
diluents
LD100 Muguga
4133
17% survivors.
Presence of CTL
correlated with
survival.
Graham et al.
(2006)
DNA (PcDNA4//
V5-HIS)
PIM 3 × 1 mg  i.d. 2 immunized
1 control
Plasmid only LD100 Katete 1 PIM immunized
animal with CTL
survived. The other
PIM animal had
MHC  class I
unrestricted CTL
and was
susceptible, as was
the control.
Ververken et al.
(2008)
Flt3 + GM-SCF
DNA/MVA
Tp1, Tp2, Tp4,
Tp5 and Tp8
0.5 mg of FLT3
and
GM-CSF/0.5 mg
DNA
(each)/5 × 108
p.f.u. MVA
i.d. 12 immunized
8 controls
Immunized
with vaccine
diluents
LD100 Muguga
4133
All animals died,
but the control
group died faster
indicating some
effect of
immunization.
Mwangi et al.
(2011)
The results derived from three published experimental trials with schizont antigens are presented. Abbreviations: CP(canary pox); i.d. (intradermal); Flt3L (FMS-like tyrosine
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oinase ligand); GM-CSF (granulocyte-macrophage colony-stimulating factor); MVA
NA  experiment, although the control animal was susceptible to challenge, it did n
uccessful. One study using CpG oligodeoxynucleotides and recom-
inant PIM antigen resulted in priming of cytolytic CD4+ T-cells
Graham et al., 2007b). A study using immunization with DNA
ncoding the PIM antigen in two animals gave equivocal results
Ververken et al., 2008). The most successful approaches have used
t least one viral vectored antigen delivery system in a prime-boost
ormat (Table 3). In order to facilitate immunogenicity studies,
attle carrying BoLA class I alleles that present the known Tp epi-
opes were used. For example, cattle with the BoLA-A18 haplotype
hould respond to the Tp1214–224 epitope (Table 2). The antigens
ested so far derive from the Muguga parasite isolate and cat-
le were given a homologous LD100 sporozoite needle challenge.
 prime-boost regimen in 24 cattle primed with a mix  of plas-
ids (DNA prime) or a mix  of recombinant canary pox virus (CP
rime) expressing ﬁve antigens (Tp1, Tp2, Tp4, Tp5 and Tp8), fol-
owed by a boost with a mix  of recombinant modiﬁed vaccinia
nkara (MVA) virus expressing the same 5 antigens, resulted in
FN- ELISpot positive results in 19 cattle (Graham et al., 2006).
our cattle exhibited CTL activity and an additional three were
ositive 2 weeks post-challenge. These seven animals were the
nly ones that were immune to challenge. When compared to the
ontrol group the overall survival rate in the experimental group
as 17%, as one animal out of four in the control group recovered
rom challenge. Although cattle were pre-selected for their BoLA
aplotype not all cattle responded with the expected Tp epitope
peciﬁcities. In addition, very few animals mounted a response
o more than one immunogen (Graham et al., 2008). Approaches
o augment the immune response to recombinant MVA  by using
he cytokines granulocyte-macrophage colony-stimulating factor
GM-CSF) and FMS-like tyrosine kinase ligand (Flt3L) elicited IFN-
 secreting CD4+ and CD8+ cells, but no CTL (Mwangi et al., 2011).
ecent unpublished data using AdHu5/MVA as a prime-boost sys-
em with the Tp1 antigen conﬁrmed an ability to prime CD8+ CTL
hat will kill peptide-pulsed targets. However, these CTL do not kill
chizont-infected cells, indicating that CTL generated by this sys-
em are qualitatively different to those generated by ITM (Svitek
t al, in preparation). Resolution of these differences will be an
mportant step forward. Currently, as in other large mammals, the
outine priming of CTLs remains a technical challenge. Our collab-
rators and we are exploring other antigen delivery systems. Untiliﬁed vaccinia Ankara); s.c. (subcutaneous); p.f.u. (plaque forming units). In the PIM
ergo a typical response (Ververken et al., 2008).
one is found, the number of CTL antigens that will be required in
an anti-schizont vaccine remains unknown.
10. Desirable qualities in a subunit vaccine for the control
of East Coast fever
One component of a target product proﬁle of a subunit vaccine
is to prime immunity against a broad-spectrum parasite chal-
lenge, e.g., that of the Muguga cocktail. The intensity, parasite
composition, and time to ﬁrst challenge post-vaccination will vary
depending on the livestock production system in which a vaccine is
deployed. Whatever the composition of the vaccine, it is desirable
that cattle undergo a mild to moderate disease reaction on chal-
lenge. For an anti-sporozoite based vaccine, this will also result
in priming a parasite-induced CTL response thereby mimicking the
live parasite method of vaccination. For an anti-schizont based vac-
cine, this should boost vaccine induced CTL speciﬁcities, and may
prime additional CTL speciﬁcities not present in the subunit vac-
cine, as is thought to occur in animals vaccinated by ITM. If these
antigens can function in a synergistic fashion, a vaccine targeting
both life cycle stages is conceptually appealing and may  be of spe-
cial value in reducing the dose of sporozoite strains not covered by
the vaccine CTL speciﬁcities. Maintaining an adequate level of pro-
tective antibody and CTL responses in a combination vaccine may
be less challenging than for either one alone. One concern that will
need to be addressed is whether recovery from an infection inter-
feres with the subsequent quality and longevity of vaccine induced
immune responses.
11. Conclusions
Substantial advances have been made in the identiﬁcation and
characterization of candidate vaccine antigens of T. parva.  Although
time consuming, the technical challenge of identifying T. parva CTL
antigens has been largely overcome. What is not clear at this stage
is the identity and number of sporozoite and/or schizont antigens
that will be required to prime broad-spectrum immunity, and how
to induce a robust CTL response. The application of more modern
approaches to vaccine-related research (Koff et al., 2013; Nakaya
and Pulendran, 2015) should lead to improved understanding
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nd proﬁling of the immune response to ITM and experimental
accines. Hence, the prospects for developing a subunit vaccine
or the control of ECF are good. The buffalo wildlife reservoir of
. parva remains a confounding factor. However, we  anticipate
 greater understanding of the differences between cattle- and
uffalo-derived T. parva, as more whole genome sequence data
ccumulate. In the interim, commercialization of the Muguga
ocktail ITM vaccine is good news for the cattle industry in Africa.
t is reasonable to expect improvements in the manufacture and
elivery of this vaccine as experience in its use in different farming
ystems accumulates.
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